Guidelines for individualized management
The American Academy of Family Physicians recommends that management of menopausal symptoms follow an individualized approach, based on shared decision-making with the patient. For the treatment of hot flashes, cognitive behavioral therapy and clinical hypnosis have demonstrated efficacy in reducing, in the short term, vasomotor symptoms and associated sleep disturbances.
In contrast, currently available evidence does not confirm a clinically relevant benefit of other non-pharmacologic interventions, such as herbal or botanical supplements, physical exercise, and acupuncture.
For genitourinary syndrome of menopause, which includes vaginal dryness and dyspareunia, non-hormonal vaginal lubricants and moisturizers represent a reasonable first-line option and, according to available data, are not inferior to local estrogen treatments.
Vaginal moisturizers are generally used several times per week to alleviate vaginal dryness, while lubricants are indicated as needed for painful intercourse. Additional therapeutic options include low-dose vaginal estrogens, oral ospemifene, and intravaginal DHEA.
Treatment choice should be guided by symptom severity and patient preferences. In women who choose vaginal estrogens, a benefit on urge urinary incontinence and prevention of recurrent urinary infections may also be observed. With low-dose vaginal estrogen therapy, endometrial protection with progesterone is generally not required.
First signs of perimenopause
The first signs of perimenopause, or menopausal transition, include menstrual irregularities, with variations of at least 7 days from the usual cycle length, followed in later phases by amenorrhea intervals of 60 days or more.
Among the most characteristic symptoms are hot flashes and night sweats — the vasomotor symptoms — which affect 50–80% of women. More recent studies indicate, however, that the most frequently reported complaints also include fatigue, physical and mental exhaustion, irritability, depressed mood, sleep disturbances, anxiety, and digestive complaints.
Brain fog, headache, joint and musculoskeletal pain, and skin changes may also appear.
Managing hot flashes without hormone therapy
For the management of hot flashes without hormone therapy, the interventions with the best scientific support include non-hormonal medications and behavioral therapies. Approved or commonly used medications include:
- Paroxetine (7.5 mg/day): the only FDA-approved SSRI, with a 10–25% symptom reduction versus placebo
- Venlafaxine (37.5–75 mg/day) and escitalopram (10–20 mg/day): 10–25% symptom reduction
- Fezolinetant (45 mg/day): neurokinin 3 receptor antagonist, reduces symptoms by 20–25%; requires liver function monitoring
- Gabapentin (300–800 mg 3 times/day): 10–20% symptom reduction
Non-hormonal treatments for vasomotor symptoms — RCT-based comparison
| Treatment and dosage | Estimated efficacy (vs placebo) | Main limitations |
|---|---|---|
| SSRI / SNRI | ||
| Paroxetina mesilato 7,5 mg/notte (unica FDA-approvata per questa indicazione) | ≈10–25% riduzione frequenza vampate | Sonnolenza, aumento di peso, calo della libido; interazioni con tamoxifene; ipertensione |
| Citalopram orale 10–30 mg/die | ≈5–35% riduzione frequenza vampate | Sonnolenza, aumento di peso, calo della libido; ipertensione |
| Desvenlafaxina orale 100 mg/die | ≈15–25% riduzione sintomi moderati-severi | Insonnia, nausea, calo della libido; ipertensione |
| Escitalopram orale 10–20 mg/die | ≈20% riduzione frequenza vampate | Sonnolenza, aumento di peso, calo della libido; ipertensione |
| Venlafaxina orale 37,5–75 mg/die | ≈10–25% riduzione frequenza vampate | Insonnia, nausea, calo della libido; ipertensione |
| Antagonisti del recettore della neurochinina 3 (NK3) | ||
| Fezolinetant orale 45 mg/die | ≈20–25% riduzione sintomi moderati-severi | Dati di sicurezza a lungo termine limitati; warning FDA: monitorare enzimi epatici |
| Altri farmaci | ||
| Gabapentin orale 300–800 mg × 3/die | ≈10–20% riduzione frequenza vampate | Sonnolenza dose-dipendente, aumento di peso, vertigini |
| Pregabalin orale 75–150 mg × 2/die | ≈15–25% riduzione frequenza vampate | Bocca secca, vertigini, stipsi, sonnolenza |
| Oxibutinina orale 2,5–5 mg × 2/die (anche formulazione a rilascio prolungato) | ≈30–50% riduzione frequenza vampate | Bocca secca, stipsi, sonnolenza; rischio di delirium negli anziani |
| Clonidina orale 0,025–0,1 mg/die | ≈10–20% riduzione frequenza vampate | Vertigini, ipotensione |
| Terapie comportamentali | ||
| Terapia cognitivo-comportamentale (CBT) — sessioni di gruppo bisettimanali o autogestite | ≈15–25% riduzione vs cure abituali | Disponibilità limitata di terapeuti formati; confronto ridotto con controlli attenzione |
| Ipnosi clinica — sessioni settimanali da 45 min | ≈45–55% riduzione vs controllo attenzione | Disponibilità limitata; studi condotti principalmente da un solo gruppo di ricerca |
Rif.: [7] — Efficacia basata su RCT pubblicati con placebo o comparatori non attivi; non ponderata per dimensione o qualità degli studi. AE = eventi avversi.
Risks and benefits of Hormone Replacement Therapy
Hormone replacement therapy has a benefit-risk profile that requires careful and personalized clinical assessment.
Main benefits
- Reduction of hot flashes by approximately 75%
- Reduction of fracture risk (all fractures: RR 0.72–0.78)
- Reduction of diabetes mellitus risk
- Reduction of colorectal cancer risk with combined estrogen-progestin therapy
Main risks
- Stroke: increased risk (RR 1.17–1.39)
- Venous thromboembolism: increased risk (RR 1.60)
- Breast cancer: increased risk with long-term combined estrogen-progestin therapy (RR 1.27); not with estrogen alone
- Gallbladder disease: increased risk (RR 1.64–1.78)
The timing of treatment initiation is crucial: in women who start HRT close to menopause onset, particularly between 50 and 59 years, the benefit-risk ratio is more favorable. Initiation after age 60 or more than 10 years after menopause is associated with increased cardiovascular risk. The transdermal route is generally preferred over the oral route due to its lower impact on coagulation mechanisms.
Abdominal weight gain during menopause
Abdominal weight gain during menopause depends primarily on changes in body composition rather than an increase in overall weight. The menopausal transition is associated with a doubling of the rate of fat accumulation and a reduction in lean mass, with selective increase in abdominal visceral fat even without significant changes in body weight.
This phenomenon is primarily related to estrogen reduction, which leads to decreased energy expenditure and redistribution of adipose tissue.
Strategies to counteract it
- Mediterranean diet: associated with reduced risk of overweight and obesity and improved cardiometabolic profile
- Resistance exercise: useful for preserving muscle mass and improving metabolism
- Caloric restriction combined with qualitative dietary improvement
- Regular physical activity: attenuates weight gain and improves metabolic parameters
Hormone therapy may contribute to improving body fat distribution, but it is not indicated as a treatment for central obesity.
Official age of menopause
Menopause is defined when 12 consecutive months of amenorrhea have elapsed, in the absence of other pathologic causes. The mean age of menopause is 51.4 years (standard deviation 3.3 years) and in 90% of cases natural menopause occurs between 45 and 56 years.
In Europe the mean age ranges between 50 and 53 years, while in North America it falls between 50 and 51 years. Menopause is defined as early when it occurs between 40 and 45 years, and premature when it appears before age 40.
Blood tests to confirm menopause
In women over age 40, routine hormonal testing to confirm menopause is not recommended. Diagnosis is primarily based on age, menstrual irregularities, and the presence of vasomotor symptoms. FSH and estradiol levels show wide variability during perimenopause and do not reach stably postmenopausal values until 3–6 years after the last menstrual period.
When hormonal tests are indicated
- Suspicion of menopause before age 40, in the context of possible premature ovarian insufficiency
- Infertility evaluation
- Situations following hysterectomy without bilateral oophorectomy
Anti-Müllerian hormone (AMH) may be useful in estimating time to the final menstrual period, with predictive capacity superior to FSH.
Osteoporosis prevention after menopause
Osteoporosis prevention after menopause requires a multifactorial approach integrating lifestyle measures and, in high-risk cases, pharmacologic therapy.
Lifestyle measures
- Calcium: 1000–1200 mg/day, preferably through diet
- Vitamin D: 400–1000 IU/day, with serum 25-hydroxyvitamin D levels above 20–30 ng/mL
- Physical exercise: weight-bearing and resistance exercises
- Smoking cessation and alcohol moderation
- Fall prevention
Pharmacologic therapies (women at high fracture risk)
- Bisphosphonates (alendronate, risedronate, zoledronate): reduce the risk of vertebral, proximal femur, and non-vertebral fractures
- Denosumab: reduces the risk of vertebral fractures by 68%, hip fractures by 40%, and non-vertebral fractures by 20%
- Menopausal hormone therapy: effective in fracture prevention in selected women
Postmenopausal osteoporosis medications — efficacy and safety comparison
| Drug | Mechanism | Dose | Vertebral fracture reduction | Hip fracture reduction | Main adverse effects |
|---|---|---|---|---|---|
| Antiriassorbitivi — Bifosfonati | |||||
| Alendronato | Si legano all'idrossiapatite ossea, inibiscono il riassorbimento osteoclastico | 10 mg/die o 70 mg/settimana per os | −44% | −40% | Irritazione GI, dolori MSK; raramente ONJ e AFF |
| Risedronato | 5 mg/die, 35 mg/settimana o 150 mg/mese per os | −36% | −26% | Come alendronato | |
| Ibandronato | 2,5 mg/die o 150 mg/mese per os; o 3 mg IV ogni 3 mesi | −31% | ND | Come alendronato | |
| Acido zoledronico | 5 mg/anno IV | −56% | −42% | Reazione di fase acuta, compromissione renale, ipocalcemia; raramente ONJ e AFF | |
| Antiriassorbitivi — Inibitori RANK ligando | |||||
| Denosumab | Anticorpo monoclonale anti-RANKL; inibisce formazione e funzione degli osteoclasti | 60 mg ogni 6 mesi s.c. | −68% | −40% | Infezioni cutanee, ipocalcemia; perdita ossea rapida alla sospensione — non interrompere senza piano di transizione |
| Anabolici — Agonisti recettore PTH | |||||
| Teriparatide (PTH 1-34) | Stimola la formazione ossea | 20 µg/die s.c. | −74% | ND | Ipercalcemia, crampi, nausea, cefalea, ipotensione; controindicato in metastasi ossee e osteosarcoma |
| Abaloparatide (PTHrP 1-34) | Stimola la formazione ossea | 80 µg/die s.c. | −87% | ND | Come teriparatide |
| Anabolici-antiriassorbitivi combinati | |||||
| Romosozumab | Anticorpo anti-sclerostina; aumenta formazione e riduce riassorbimento osseo | 210 mg/mese s.c. (12 mesi) | −73% | −38% | Artralgie, cefalea, eventi CV; controindicato in ictus o IM recente |
Rif.: [22, 23, 24] — Riduzioni del rischio vs placebo in RCT e meta-analisi. ND = non dimostrato. ONJ = osteonecrosi della mascella. AFF = frattura femorale atipica. GI = gastrointestinale. MSK = muscoloscheletrico.
Clinical algorithm for osteoporosis fracture prevention
| Phase | Clinical content |
|---|---|
| Prevenzione non farmacologica | Calcio e vitamina D adeguati (dieta + supplementi); esercizio di resistenza e bilanciamento; valutazione e prevenzione cadute; cessazione del fumo; alcol ≤2 unità /die; mantenere BMI ≥20 |
| Screening — fattori di rischio clinici | Precedente frattura; uso cronico di glucocorticoidi; artrite reumatoide; storia familiare di frattura d'anca; BMI <20; alcol ≥3 unità /die; fumo attivo; osteoporosi secondaria (iperparatiroidismo, IRC, deficit di vitamina D) |
| Segni fisici di frattura vertebrale | Perdita di altezza; aumento della distanza occipite-parete |
| Stima del rischio | Densitometria ossea (MOC-DXA) se indicata; imaging spinale (Rx o VFA) per vertebre; stima FRAX a 10 anni (≥20% per frattura osteoporotica maggiore o ≥3% per anca = soglia terapeutica) |
| Criterio di trattamento farmacologico | Precedente frattura vertebrale o d'anca; T-score ≤−2,5; FRAX ad alto rischio (≥20%/≥3%) |
| Rischio alto → terapia antiriassorbitiva | Bifosfonato orale o IV (3 anni IV / 5 anni orale), poi rivalutazione; oppure denosumab (continuare senza interruzione per evitare perdita ossea rebound) |
| Rischio molto alto → agente anabolico | Teriparatide o abaloparatide (18–24 mesi); romosozumab (12 mesi); seguire sempre con antiriassorbitivo |
| Monitoraggio | Aderenza terapeutica, eventi avversi, cadute, nuove fratture; ripetere MOC-DXA dopo 2–3 anni dall'inizio |
| Criteri per invio allo specialista | Causa secondaria confermata; rischio molto elevato; mancata risposta alla terapia; necessità di sospendere denosumab |
Rif.: [22, 23, 24, 25, 26] — Adattato dalle linee guida Endocrine Society e Cochrane 2025.
- Menstruation ceasing before age 40 (premature menopause)
- Sudden bone pain or fracture from minimal trauma
- Very intense and debilitating hot flashes
- Vaginal bleeding after confirmed menopause
- Cardiovascular symptoms (chest pain, dyspnea) during HRT
Natural remedies for insomnia and irritability
For menopause-associated insomnia, the non-pharmacologic interventions with the greatest scientific support include mind-body approaches and behavioral therapies.
Interventions with best evidence for sleep
- Mindfulness: found most effective in meta-analysis, with significant improvement in sleep quality
- Cognitive behavioral therapy (CBT): 15–25% reduction in sleep disturbances
- Yoga and Qigong: associated with persistent sleep benefits
- Music therapy and dance therapy: favorable effects especially on psychological well-being
- Physical exercise: low and moderate intensities improve sleep
- Aromatherapy, acupuncture, and massage: associated with significant improvement in sleep quality
For irritability and anxiety, mind-body therapies — including mindfulness, music therapy, and dance therapy — show moderate to marked effects in reducing anxiety and depressive symptoms. Interventions lasting 12 weeks or more appear to be associated with more consistent results.
Caution regarding supplements: herbal and botanical supplements (phytoestrogens, black cohosh, etc.) lack sufficient quality evidence to be recommended for the management of menopausal symptoms, whether vasomotor or sleep-related.
Sexual desire and vaginal dryness
Menopause may be associated with reduced sexual desire and vaginal dryness, in the context of genitourinary syndrome of menopause, which affects 45–77% of women.
Treatment of vaginal dryness
- Non-hormonal vaginal lubricants and moisturizers: first-line, not inferior to estrogen therapies
- Vaginal estrogens (cream, tablet, ring): reduce vaginal dryness and dyspareunia
- Intravaginal DHEA (prasterone): improves dryness and dyspareunia
- Oral ospemifene (60 mg/day): improves vaginal dryness and dyspareunia
Treatment of reduced sexual desire
- Transdermal testosterone (1% cream, 0.5–1 ml/day): used off-label, with evidence of 1–1.4 additional satisfying sexual events per month
- Menopausal hormone therapy: may improve sexual symptoms if it controls the most bothersome vasomotor symptoms
- Psychosocial interventions: sexual education, cognitive therapy, and couples therapy
Therapeutic options for sexual dysfunction in menopause — evidence and safety profile
| Treatment | Indication | Strength of evidence | Main adverse effects |
|---|---|---|---|
| Approcci non farmacologici | |||
| Psicoterapia sessuale (educazione, terapia cognitiva, terapia di coppia) | Disfunzione sessuale in generale | Variabile; principalmente studi su piccole popolazioni eterogenee | Non applicabile |
| Fisioterapia del pavimento pelvico; dispositivo a vuoto clitorideo (FDA-approvato) | Disfunzione dell'eccitazione, dispareunia | Variabile per popolazione | Non applicabile |
| Secchezza vaginale e dispareunia | |||
| Lubrificanti vaginali (uso al bisogno durante l'attività sessuale) | Dispareunia da secchezza | Evidenza moderata per riduzione della dispareunia | Ingredienti variabili; alcuni possono causare irritazione o alterare la motilità spermatica |
| Idratanti vaginali (uso regolare, più volte/settimana) | Secchezza, prurito, irritazione | Evidenza solida per riduzione della dispareunia | Vedi lubrificanti |
| Estrogeni vaginali (compressa, ovulo, crema, gel, anello) — FDA-approvati | Secchezza vaginale postmenopausale | Efficacia moderata per secchezza e dispareunia, simile in tutte le formulazioni | Perdite vaginali, candidiasi vulvovaginale, spotting; dipende da dose e formulazione |
| Prasterone intravaginale 6,5 mg/notte (DHEA) | Secchezza e dispareunia | Evidenza solida per riduzione della dispareunia | Perdite vaginali |
| Ospemifene orale 60 mg/die (SERM) | Secchezza e dispareunia | Evidenza moderata per miglioramento della funzione sessuale | Sintomi vasomotori, perdite vaginali, candidiasi; può aumentare lo spessore endometriale |
| Ipoattività del desiderio sessuale — postmenopausa | |||
| Testosterone transdermico 1% crema (0,5–1 ml/die) — off-label nella maggior parte dei Paesi | HSDD postmenopausale | Evidenza da studi di bassa qualità per questa formulazione; evidenza solida per testosterone transdermico in generale; +1–1,4 eventi sessuali soddisfacenti/mese | Acne, irsutismo, aumento di peso |
| Ipoattività del desiderio sessuale — premenopausa | |||
| Flibanserin 100 mg/notte per os | HSDD premenopausale (FDA-approvato) | Effetto modesto (+0,5–0,65 eventi sessuali soddisfacenti/mese) | Sonnolenza, sedazione (28%); sincope; controindicato con alcol e inibitori CYP3A4 |
| Bremelanotide 1,75 mg s.c. 45 min prima dell'attività sessuale | HSDD premenopausale (FDA-approvato) | Effetto modesto sul desiderio vs placebo (0,35 punti su 5); nessuna evidenza su eventi sessuali soddisfacenti | Nausea (40%), vampate (20%), cefalea (11%) |
Rif.: [31, 32] — HSDD = ipoattività del desiderio sessuale (Hypoactive Sexual Desire Disorder). La disponibilità di trattamenti ormonali e non ormonali varia tra i Paesi.
Palpitations and anxiety during menopause
Menopause may be associated with palpitations and anxiety. Palpitations — perceived as a rapid or irregular heartbeat — are common in menopausal women, with a prevalence of 73.6% considering all symptom intensities.
Studies show that moderate-to-severe palpitations are independently associated with vasomotor symptoms (OR 1.18) and anxiety (OR 1.19), but not with age, menopausal status, heart rate, presence of arrhythmias, or caffeine and alcohol consumption.
Anxiety during the menopausal transition
- Some prospective studies have not documented an increase in anxiety disorders during the menopausal transition
- Other studies (SWAN, PATH) have shown an increase in anxiety symptoms in women with low pre-menopausal anxiety
- Somatic anxiety may predict the onset of moderate or severe vasomotor symptoms, suggesting a bidirectional relationship
- The risk of major depressive episodes increases 2 to 5 fold during perimenopause compared with late premenopause
The neuroendocrine mechanisms involved include estrogen and progesterone fluctuations, which may cause an imbalance between excitatory and inhibitory central nervous system pathways, with involvement of neurotransmitters such as GABA, serotonin, and dopamine.
Frequently Asked Questions
The menopausal transition begins with menstrual irregularities: variations of at least 7 days from the usual cycle length, followed by amenorrhea periods of 60 days or more in advanced phases. Vasomotor symptoms (hot flashes and night sweats) affect 50–80% of women.
Recent studies show that the most frequently reported symptoms also include fatigue, irritability, depressed mood, sleep disturbances, anxiety, brain fog, and musculoskeletal pain.
Rif.: [2, 3, 4, 5, 6]
The non-hormonal medications with the strongest evidence include paroxetine 7.5 mg/day (the only FDA-approved SSRI), venlafaxine, escitalopram, fezolinetant 45 mg/day, and gabapentin, with symptom reductions between 10% and 25% versus placebo, up to 25% for fezolinetant.
Among behavioral therapies, CBT reduces symptoms by 15–25% and clinical hypnosis by 45–55%. Acupuncture, phytoestrogens, physical exercise, and black cohosh do not significantly surpass placebo.
Rif.: [2, 7]
HRT reduces hot flashes by approximately 75%, fracture risk (RR 0.72–0.78), diabetes mellitus risk, and colorectal cancer risk (with combined therapy). However, it increases the risk of stroke (RR 1.17–1.39), venous thromboembolism (RR 1.60), breast cancer with long-term estrogen-progestin therapy (RR 1.27), and gallbladder disease (RR 1.64–1.78).
The benefit-risk ratio is more favorable between 50 and 59 years. The transdermal route reduces thromboembolic risk compared with the oral route.
Rif.: [8, 9, 10, 11]
Estrogen decline causes redistribution of adipose tissue toward the abdominal visceral compartment, doubling of fat accumulation rate, and loss of lean mass, even without a significant increase in total body weight.
The most effective strategies include the Mediterranean diet, resistance exercise to preserve muscle mass, qualitative caloric restriction, and regular physical activity. HRT may improve fat distribution but is not a treatment for central obesity.
Rif.: [13, 14, 15, 16, 17]
Menopause is defined after 12 consecutive months of amenorrhea without known pathologic causes. The mean age is 51.4 years (SD 3.3 years), with 90% of cases between 45 and 56 years. In Europe the mean ranges between 50 and 53 years.
Menopause is defined as early between 40 and 45 years, and premature (premature ovarian insufficiency, POI) before age 40 — a condition requiring prompt specialist evaluation.
Rif.: [2, 11, 14, 18]
No, in women over 40 the diagnosis of menopause is primarily clinical, based on age, menstrual irregularities, and vasomotor symptoms. FSH and estradiol levels vary widely during perimenopause and do not reach stably postmenopausal values for 3–6 years after the last menstrual period.
Hormonal testing is indicated when premature menopause (before age 40) is suspected, for infertility evaluation, or after hysterectomy without oophorectomy. AMH has superior predictive capacity over FSH in estimating time to menopause.
Rif.: [2, 19, 20, 21]
The approach is multifactorial: calcium 1000–1200 mg/day (preferably from dietary sources), vitamin D 400–1000 IU/day with target serum levels above 20–30 ng/mL, weight-bearing exercise, smoking cessation, alcohol moderation, and fall prevention.
In women at high fracture risk, bisphosphonates (alendronate, risedronate, zoledronate), denosumab — which reduces vertebral fractures by 68% — or menopausal hormone therapy in appropriate candidates are used.
Rif.: [22, 23, 24, 25, 26]
Mind-body therapies have the strongest scientific support. Mindfulness was the intervention found most effective in meta-analysis for sleep quality; followed by CBT (15–25% reduction in disturbances), yoga, qigong, low or moderate-intensity physical exercise, aromatherapy, and acupuncture. For irritability and anxiety, interventions lasting ≥12 weeks show more consistent results.
Herbal and botanical supplements — including phytoestrogens and black cohosh — lack sufficient quality evidence for recommendation for either sleep or vasomotor symptoms.
Rif.: [1, 27, 28, 29, 30]
For vaginal dryness, non-hormonal lubricants and moisturizers represent the first line and are not inferior to local vaginal estrogens (cream, tablet, ring). Additional options include intravaginal DHEA (prasterone) and oral ospemifene 60 mg/day.
For reduced desire, off-label transdermal testosterone (1% cream, 0.5–1 ml/day) increases satisfying sexual events by 1–1.4 per month. Psychosocial interventions — sexual education, cognitive therapy, and couples therapy — are complementary and indicated.
Rif.: [1, 28, 31, 32]
Palpitations are common during menopause, with a prevalence of 73.6% considering all intensity levels. Moderate-to-severe palpitations are independently associated with vasomotor symptoms (OR 1.18) and anxiety (OR 1.19), but not with arrhythmias, heart rate, or caffeine consumption.
Anxiety may increase during the menopausal transition — SWAN and PATH studies show an increase in women with low baseline anxiety — and the risk of major depressive episodes increases 2 to 5 fold in perimenopause. Hormonal fluctuations alter the serotonergic, dopaminergic, and GABAergic systems. It is important to rule out cardiac and thyroid causes with your physician.
Rif.: [14, 33, 34, 35]
For information on gynecologic examination and the initial diagnostic pathway, visit the portal dedicated to clinical gynecology.
iltuoginecologo.it → Ginecologia clinica
Request a Specialist Consultation
For a personalized assessment of menopausal symptoms, candidacy for hormone replacement therapy, or management of osteoporosis and genitourinary syndrome, you may request a specialist consultation.
Book a Consultation →